Medical devices: action needed to address the lack of patient protection

- The Implant Files scandal is yet another warning of the urgency of the situation and of the weaknesses of the existing legislation, at the expense of patients’ safety.

Whether it is a breast implant or a cardiac pacemaker, marketing of a medical device is not subject to marketing authorisation (MA). Only a CE marking (European compliance) is required, which is often conferred by private organisations, on the basis of technical documentation (1). This situation is conducive to abuse and to disasters.

Medical device vigilance: a lack of human resources and responsiveness. The Implant Files, a global investigation by journalists, brought to light numerous failings in the medical device sector worldwide, which are detrimental to patients (2). In the absence of an MA, the authorities mainly react after a malfunction has been reported, or has been identified by active medical device monitoring. Such surveillance is weak in France, as shown by a report from the “Inspection Générale des Affaires Sociales (IGAS)” (the French government audit office for health and social security) (3). “In 2017 alone, the 19 assessors [from the French Health Products Agency] (...) handled the processing of 17,142 reports, of which 13,467 required investigation (major and critical safety alerts). Such a high workload forces them to work on a “just-in-time” basis (...) and to take a light-touch approach to some major cases (around 60%) (...). Overall, this leads to highly variable time frames for implementing corrective measures following an incident, which are relatively long (ranging from 21 to 215 days, with an average of 95 days) and are unrelated to the severity of the incident” (3).

Protect patients before and after marketing. In response, the French government has announced actions primarily aimed at “reinforcing the assessment and supervision of practices for medical device implantation, in particular for those carrying the greatest risk” and “guaranteeing the traceability of implantable medical devices in healthcare establishments” (4).

Medical device vigilance needs to be reinforced considerably, as does the assessment of practices and traceability. However, the need to control entry onto the European medical device market must not be overlooked, so that dangers are detected before patients are exposed to them. The pharmaceutical sector shows that an MA is not in itself sufficient for safeguarding the interests of patients, especially when the requirements for obtaining an MA are not rigorous. However, establishing a European MA for medical devices would represent significant progress, and would indicate that public authorities recognise their core responsibility in this area.

The new European regulation which will come into effect in 2020 still does not provide for controlling market access for the highest risk medical devices (5). It is to be hoped that the authorities, in France and other countries, will demand that this measure will be implemented in order to protect patients, as was also proposed by a report of the French National Assembly in March 2019 (6).

Selected references from Prescrire’s literature search

5- “Nouveaux règlements européens relatifs aux dispositifs médicaux - Point d’information” 29 August 2017: 2 pages.

Advancing healthcare policy in Europe

Via its policy advocacy, Prescrire acts as a force for change in health policies, first and foremost in the interest of patients. See the “Advancing healthcare policy” section of our website for a complete recap of Prescrire’s policy advocacy actions, including this recent item:

- A call for timely application of the new rules on medical devices and complete transparency concerning high-risk medical devices with public access to Eudamed

- Prescrire’s response to the EMA Regulatory Science strategy to 2025: refocus on public health mission as gatekeeper and strengthen pharmacovigilance

See online at english.prescrire.org > Topics > Advancing healthcare policy